A published case report is underway, though, and we can expect another report from these doctors in a couple of months
For #Investors and #Media: Were pleased to share that we had a successful EndofPhase 2 meeting with the FDA regarding the development of BPL003, our proprietary intranasal formulation of mebufotenin benzoate, for treatmentresistant depression
This product has not been independently tested for efficacy or safety, but each ingredient has been scientifically studied and shown to safely deliver positive results and improve the conditions noted
You might vomit once or twice during the first few days at a new dose, then not again as you adjust
Osteoporosis: Prevention and Treatment
This matters because physicians will soon face patients who arrive already dosed, armed with AI summaries that may or may not match the evidence